SCHEMBL4757017

SCHEMBL4757017

Cc1oc2ccccc2c(=O)c1O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.61
TP53 P04637 2/20 0.61
RET P07949 1/20 0.61
TSHR P16473 1/20 0.61
ALOX12 P18054 1/20 0.61
KDR P35968 1/20 0.61
HTT P42858 1/20 0.61
KDM4E B2RXH2 5/20 0.59
CYP3A4 P08684 5/20 0.59
MEN1 O00255 3/20 0.59
KMT2A Q03164 3/20 0.59
ALOX15 P16050 2/20 0.59
MAPK1 P28482 2/20 0.59
CA12 O43570 1/20 0.59
CA1 P00915 1/20 0.59
CA2 P00918 1/20 0.59
ABCB1 P08183 1/20 0.59
CALM1 P0DP23 1/20 0.59
AR P10275 1/20 0.59
PKM P14618 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL744133 0.84 KDM4E (0.60) LMNATP53RETTSHRALOX12
SCHEMBL6719113 0.80 MAOA (0.61) LMNATP53RETTSHRALOX12
SCHEMBL1180659 0.80 KDM4E (0.62) LMNATP53RETTSHRALOX12
SCHEMBL15676117 0.78 NMUR2 (0.68) LMNATP53RETTSHRALOX12
Xanthone SCHEMBL11245548 0.77 MAOA (0.86) LMNATP53KDM4ECYP3A4MEN1
SCHEMBL8802227 0.77 KDM4E (0.59) LMNATP53RETTSHRALOX12
SCHEMBL10824491 0.77 DDR2 (0.59) LMNARETHTTKDM4ECYP3A4
SCHEMBL13978680 0.77 MAOA (0.57) LMNATP53RETTSHRALOX12
SCHEMBL28032733 0.77 CYP2C9 (0.57) LMNATP53RETTSHRALOX12
SCHEMBL28301960 0.77 CYP3A4 (0.59) LMNATP53RETTSHRALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1978997-A1 TRANSDERMAL DELIVERY OF PHARMACEUTICAL AGENTS Apollo Life Sciences Limited (AU) 2008-10-15 EP claimed
US-20070243132-A1 Transdermal delivery of pharmaceutical agents APOLLO LIFE SCIENCES LIMITED (AU) 2007-10-18 US claimed
WO-2007070983-A1 TRANSDERMAL DELIVERY OF PHARMACEUTICAL AGENTS APOLLO LIFE SCIENCES LIMITED (AU) 2007-06-28 WO claimed
WO-2019195430-A1 STREPTOCOCCUS MUTANS GLUCOSYL TRANSFERASE INHIBITORS FOR DENTAL CARIES THERAPY UAB RESEARCH FOUNDATION (US) 2019-10-10 WO disclosed
US-9828407-B2 Water soluble and activable phenolic derivatives with dermocosmetic and therapeutic applications and process for preparing said derivatives LIBRAGEN (FR) 2017-11-28 US disclosed
WO-2008154705-A1 TRANSDERMAL DELIVERY OF ACTIVE AGENTS APOLLO LIFE SCIENCES LIMITED (AU) 2008-12-24 WO disclosed
EP-1978997-A1 TRANSDERMAL DELIVERY OF PHARMACEUTICAL AGENTS Apollo Life Sciences Limited (AU) 2008-10-15 EP disclosed
WO-2007131286-A1 NANOSTRUCTURES SUITABLE FOR DELIVERY OF AGENTS APOLLO LIFE SCIENCES LIMITED (AU) 2007-11-22 WO disclosed
US-20070243132-A1 Transdermal delivery of pharmaceutical agents APOLLO LIFE SCIENCES LIMITED (AU) 2007-10-18 US disclosed
WO-2007070983-A1 TRANSDERMAL DELIVERY OF PHARMACEUTICAL AGENTS APOLLO LIFE SCIENCES LIMITED (AU) 2007-06-28 WO disclosed
EP-1124814-B1 AROMATIC DERIVATIVES AND IRON COMPLEXES THEREOF FOR THE USE AS NORMALISING AGENTS OF THE IRON LEVEL MEDIDOM LAB (CH) 2002-12-18 EP disclosed
US-6455578-B1 IRON CHELATING AGENTS FOR TREATMENT OF IRON OVERLOAD AND ANEMIA. LABORATOIRE MEDIDOM S.A. (CH) 2002-09-24 US disclosed
EP-1124814-A1 AROMATIC DERIVATIVES AND IRON COMPLEXES THEREOF FOR THE USE AS NORMALISING AGENTS OF THE IRON LEVEL LABORATOIRE MEDIDOM S.A. (CH) 2001-08-22 EP disclosed
WO-2000026205-A1 AROMATIC DERIVATIVES AND IRON COMPLEXES THEREOF FOR THE USE AS NORMALISING AGENTS OF THE IRON LEVEL LABORATOIRE MEDIDOM S.A. (CH) 2000-05-11 WO disclosed